CSL Limited

Introduction
CSL Limited is a leading global biotechnology company headquartered in Melbourne, Australia. Founded in 1916 as the Commonwealth Serum Laboratories, CSL has grown into a multinational leader specializing in plasma-derived therapies, vaccines, and innovative biotechnology medicines. The company operates through its subsidiaries CSL Behring (plasma therapies) and Seqirus (influenza vaccines), making it one of the largest players in the biopharmaceutical and vaccine industries.

Mission and Vision

Mission: To save lives and protect the health of people with life-threatening medical conditions.
Vision: To be a trusted global leader in biotechnology, delivering innovative therapies that improve and extend patients’ lives.

Products and Services

Plasma-Derived Therapies: Treatments for hemophilia, immune deficiencies, and other rare and serious diseases.
Vaccines (Seqirus): One of the world’s largest producers of influenza vaccines.
Specialty Biologics: Therapies for transplant medicine, respiratory conditions, and cardiovascular diseases.
Research & Development: Focus on gene therapy, recombinant technologies, and next-generation vaccines.

Growth and Innovation
CSL has evolved from a national public health laboratory into a top-10 global biotech company. The acquisition of Seqirus (via Novartis’ flu vaccine business) positioned CSL as a world leader in influenza prevention. The company continues to expand into gene therapy, recombinant proteins, and rare disease innovation, supported by significant investments in global R&D hubs and manufacturing facilities.

Global Impact
CSL operates in over 35 countries and serves patients in more than 100 markets. Its plasma therapies and vaccines play a crucial role in addressing public health needs, from rare genetic disorders to global influenza protection. CSL is also committed to sustainability, aiming to reduce environmental impact and improve access to life-saving medicines worldwide.